Trishula Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.trishulatx.com
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Phase 2
Active, not recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- Combination Product: TTX-030, budigalimab, nab-paclitaxel and gemcitabineCombination Product: TTX-030, nab-paclitaxel and gemcitabineCombination Product: Nab-Paclitaxel and gemcitabine
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Trishula Therapeutics, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT06119217
- Locations
- 🇨🇳
Investigative Site, Taoyuan, Taiwan
🇺🇸Investigative SIte, Hot Springs, Arkansas, United States
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Phase 1
Completed
- Conditions
- Solid Tumor, Adult
- Interventions
- Combination Product: TTX-030 and mFOLFOX6Combination Product: TTX-030, budigalimab and mFOLFOX6Combination Product: TTX-030 and pembrolizumabCombination Product: TTX-030, nab-paclitaxel and gemcitabineCombination Product: TTX-030, budigalimab and docetaxelCombination Product: TTX-030 and budigalimabCombination Product: TTX-030, budigalimab, nab-paclitaxel and gemcitabineCombination Product: Budigalimab and mFOLFOX6
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Trishula Therapeutics, Inc.
- Target Recruit Count
- 185
- Registration Number
- NCT04306900
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Phase 1
Completed
- Conditions
- LymphomaSolid Tumor
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Trishula Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03884556
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸West Cancer Center and Research Institute, Germantown, Tennessee, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath